建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
Biosynthetic Products
In addition to contract research projects, Panlabs actively develops high-value biosynthetic products, focusing on metabolites for antifungal and anticancer applications, as well as specialized industrial enzymes.
For each development project, we leverage strain improvement, enzyme modification, or genetic engineering to select the most suitable microbial strains and optimize the fermentation process for efficient production. For target products that require semisynthetic compounds, we employ chemical or enzymatic conversion techniques to manufacture intermediates or final products, providing robust support for subsequent industrial-scale manufacturing.
For example, cytotoxic small-molecule drugs used in antibody-drug conjugates (ADCs), such as Ansamitocin P-3 (AP3) and Calicheamicin, are derived from microbial strains. These compounds undergo strain improvement, fermentation process optimization, and product purification and recovery, and have successfully completed pilot-scale production tests, enabling the supply of high-purity products at the hundred-gram scale or higher.
Additionally, through collaboration with specialized chemistry partners, we also provide semisynthetic derivatives, including N-Acetyl-Calicheamicin, Maytansinol (AP0), and Mertansine (DM1).
We are engaged in
In addition to Ansamitocin P3 (AP3) and CLM γI, Panlabs is actively developing several commercially viable products, including anticancer drugs like Doxorubicin and Staurosoprine (Midostaurin), antibiotics like Penicillin and Cephasporin C, health food products like CoQ10, as well as Antiparasite like MLB(CAS.No:1799297-76-9) etc. Most products have been developed with competitive fermentation titers and have potential for scale-up production. Our current production capacities for these products are to meet market demands and are suitable for manufacturers interested in mass production and market promotion.
Furthermore, Panlabs is dedicated to advancing biotechnology for application in the circular economy, aligning with the emerging trends in the green industry. We have carefully chosen appropriate fungal strains from our extensive microbial library, with a primary focus on mycelium production development. For example, by utilizing mycoproteins to replace animal proteins, Panlabs apply them in the next generation of sustainable meat and animal feed, contributing to carbon reduction and environmental conservation.
Compared to traditional livestock farming, the production of fungal protein (a type of plant-based protein) requires significantly less land and is much faster. This holds substantial significance and benefits considering the growing global focus on carbon reduction . We welcome enterprises from all sectors to discuss potential collaborations and co-creation.
Contact Panlabs to request samples and explore collaboration opportunities.
